The estimated Net Worth of George Jay Goldsmith is at least $33.9 Миллион dollars as of 20 May 2024. Mr Goldsmith owns over 31,207 units of COMPASS Pathways plc stock worth over $26,916,479 and over the last 3 years he sold CMPS stock worth over $6,280,724. In addition, he makes $722,792 as Co-Founder и Chairman & CEO at COMPASS Pathways plc.
Mr has made over 12 trades of the COMPASS Pathways plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 31,207 units of CMPS stock worth $246,535 on 20 May 2024.
The largest trade he's ever made was selling 95,016 units of COMPASS Pathways plc stock on 2 January 2024 worth over $843,742. On average, Mr trades about 35,737 units every 44 days since 2022. As of 20 May 2024 he still owns at least 3,929,413 units of COMPASS Pathways plc stock.
You can see the complete history of Mr Goldsmith stock trades at the bottom of the page.
George Jay Goldsmith is the Co-Founder, Chairman & CEO at COMPASS Pathways plc.
As the Co-Founder и Chairman & CEO of COMPASS Pathways plc, the total compensation of Mr Goldsmith at COMPASS Pathways plc is $722,792. There are no executives at COMPASS Pathways plc getting paid more.
Mr Goldsmith is 67, he's been the Co-Founder и Chairman & CEO of COMPASS Pathways plc since . There are no older and 3 younger executives at COMPASS Pathways plc.
George's mailing address filed with the SEC is COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON, X0, W1F 0DQ.
Over the last 3 years, insiders at COMPASS Pathways plc have traded over $12,645,913 worth of COMPASS Pathways plc stock. The most active insiders traders include George Jay Goldsmith, Ekaterina Malievskaia и Gino Santini. On average, COMPASS Pathways plc executives and independent directors trade stock every 32 days with the average trade being worth of $359,563. The most recent stock trade was executed by Ekaterina Malievskaia on 20 May 2024, trading 31,207 units of CMPS stock currently worth $246,535.
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.
COMPASS Pathways plc executives and other stock owners filed with the SEC include: